Next Article in Journal
Junín Virus Pathogenesis and Virus Replication
Next Article in Special Issue
The Baboon (Papio spp.) as a Model of Human Ebola Virus Infection
Previous Article in Journal
Function and Regulation of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / CRISPR Associated (Cas) Systems
Previous Article in Special Issue
A Characterization of Aerosolized Sudan Virus Infection in African Green Monkeys, Cynomolgus Macaques, and Rhesus Macaques
Article Menu

Export Article

Open AccessEditorial
Viruses 2012, 4(10), 2312-2316; doi:10.3390/v4102312

An Interagency Collaboration to Facilitate Development of Filovirus Medical Countermeasures

1
Chemical Biological Medical Systems Joint Vaccine Acquisition Program, 1564 Freedman Dr, Fort Detrick, MD 21702, USA
2
Office of Biodefense Research Affairs, DMID, NIAID, NIH, 6610 Rockledge, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Received: 14 October 2012 / Revised: 16 October 2012 / Accepted: 17 October 2012 / Published: 19 October 2012
(This article belongs to the Special Issue Advances in Filovirus Research 2012)
View Full-Text   |   Download PDF [153 KB, uploaded 12 May 2015]

Abstract

The Filovirus Animal Non-Clinical Group (FANG) is a US interdepartmental and interagency group established to support and facilitate the advanced development of filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. It is co-led by one representative from the Department of Defense (DoD), the first author, and one from the Department of Health and Human Services (HHS), the second author. The FANG membership includes operational level program staff and Subject Matter Experts (SME) from performing organizations as well as scientific staff and program managers from DoD and HHS funding and regulatory agencies. Focus areas include animal models, assays, reagents, product manufacture and characterization, and other interagency product development issues that will support Food and Drug Administration (FDA) licensure of safe and effective filovirus MCMs. The FANG continues to develop strategies to address broadly applicable and interagency product development challenges relevant to filovirus MCM development. This paper summarizes FANG structure and accomplishments and is meant to heighten community awareness of this government-led collaborative effort.
Keywords: biodefense; Ebola; ebolavirus; FANG; Filovirida; filovirus; Filovirus Animal Non-Clinical Group; Marburg virus; marburgvirus; medical countermeasures biodefense; Ebola; ebolavirus; FANG; Filovirida; filovirus; Filovirus Animal Non-Clinical Group; Marburg virus; marburgvirus; medical countermeasures
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kilgore, N.; Nuzum, E.O. An Interagency Collaboration to Facilitate Development of Filovirus Medical Countermeasures. Viruses 2012, 4, 2312-2316.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top